GRAIL is trading 4.1% down at $72.71 following fresh securities-fraud class action reminders tied to the company's failed NHS-Galleri cancer trial in February.
- New law-firm notices and press releases have highlighted steep prior losses and upcoming class-period deadlines, keeping legal overhang front-of-mind for investors.
- The resurfacing of litigation risks has tempered yesterday’s rebound as the market continues to weigh the impact of ongoing legal challenges.